Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.
Based on the results of the SUSTAIN trial, semaglutide is approved by the FDA for the treatment of T2DM patients.
The DIRECT trial evaluated a weight management program delivered by primary care. On average, weight reduced by 10 kg and almost half achieved and maintained remission of T2DM at 12 months after starting the intervention.
Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients
AHA 2017 Analysis of CANVAS program compared use of canagliflozin in primary or secondary prevention and found a greater benefit on CV, renal and death outcomes in those with existing CVD.
In this educational program, which was held at the ESC Congress 2017 in Barcelona, Spain, epigenetic regulation of gene expression in patients at high CV risk with diabetes was reviewed
AHA 2017 A sub-analysis of the EMPA-REG OUTCOME examined whether the benefits of empaglifozin are preserved in diabetic patients with and without PAD.
In post-ACS type 2 diabetic patients at high CV risk, there is a significant association between baseline hsCRP values and future CV outcomes.
In the TOPCAT study, diabetes and its microvascular complications carried important prognostic information regarding adverse outcomes in HFpEF patients.
Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose a drug.
This summary by Prof Ray gives insight in the high CV risk in patiens with diabetes. Treatment options and testing of these drugs in trials were discussed, including the new antidiabetic drugs, such as empagliflozin, and other novel agents, such as the PCSK9 inhibitor evolocumab.
This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017